Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Hershey Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Hershey Co trades at $176.58 (market cap $35.23B). The key difference: Hershey Co is far larger — about 42.6× Amphastar Pharmaceuticals Inc's market cap, and Hershey Co pays a 3.34% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HSY | |
|---|---|---|
Market Cap | $826.08M | $35.23B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $236.28 |
52-Week Low | $16.87 | $162.31 |
Enterprise Value | $1.22B | $40.03B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
HSY trades at $173.66, up 1.17% with recent earnings beats and easing cocoa costs supporting fundamentals. Technicals are bearish with resistance at $175, while valuation metrics like a P/E of 32.34 suggest premium pricing. The company maintains strong cash flow and a 3.22% dividend yield, with Q2 2026 earnings due July 30, 2026, as a key catalyst.
Outlook: Upside exists to the $210.33 consensus target if margin recovery continues, but high debt and volatile input costs pose risks. Analyst sentiment is cautious with 65.7% hold ratings, reflecting balanced growth and valuation concerns amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
